Cook's iMRI unit to sell Profound's TULSA-PRO in US as quarterly sales surge
Profound Medical reported an 86% rise in third-quarter revenue, set a full-year floor of $25.0 million and announced a leadership change effective in January 2027.
Profound Medical has added a U.S. distribution partner for its TULSA-PRO prostate ablation system. The company signed a supply and distribution agreement with the iMRI Division of Cook Medical, under which the system will be sold through Cook's Copernicus program. Financial terms, duration and rollout timetable were not disclosed in the material available to us.
The deal came alongside third-quarter results published on 5 November. Profound reported revenue of about $9.8 million, which it described as an 86% increase. Gross margin was 78%, and the company said its operating cash burn fell sharply. It gave no cash-burn figure in the material we reviewed.
For the full year, Profound guided to revenue of at least $25.0 million. The company did not give a breakdown of that figure by product, region or sales channel, so it is unclear how much, if any, the Cook arrangement contributes.
Profound also announced a change at the top. Richard Fabian will become chief executive officer on 14 January 2027. No further detail on the transition was available, and the company has not announced any shift in commercial or regulatory strategy.
Why it matters
- Cook's iMRI Division gives TULSA-PRO a U.S. sales route in addition to Profound's own commercial effort, though the agreement's economics and timing are undisclosed.
- A 78% gross margin and sharply lower cash burn are company-reported; the absence of a burn figure limits outside assessment of the improvement.
- U.S. hospital quality and supply teams may want clarity on how supply, service and complaint handling will be divided between Profound and Cook.
- The CEO handover on 14 January 2027 is a date to watch for any change in strategy, although none has been signalled.
Company's press release (SEC filing): Profound Medical Corp. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
